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Heart failure and renal failure commonly coexist; the prev-
alence of chronic kidney disease in heart failure patients is
nearly 25% and is associated with poor prognosis (1–3). A
substantial proportion of patients with decompensated heart
failure show further worsening of renal function during
hospitalization, increasing the risks of morbidity and mor-
tality (4–6), particularly among those with residual conges-
tion (7). Several factors, including renal hypoperfusion,
neurohormonal activation, immune-mediated damage, and
nephrotoxic effects of diuretics and neurohormonal antago-
nists, have been implicated in the pathogenesis of the
cardiorenal syndrome (8).
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Although it seems intuitive that hemodynamic factors
may be primarily responsible for worsening renal function in
acute heart failure, this does not seem to be the case (9). The
SCAPE (Evaluation Study of Congestive Heart Failure
nd Pulmonary Catheterization Effectiveness) trial found no
ink between invasively measured hemodynamic parameters
including cardiac output) and serum creatinine in 194
atients with advanced heart failure (10); only right atrial
ressure correlated weakly with renal function, suggesting a
ossible role for renal congestion, but not hypoperfusion, in
he pathogenesis of cardiorenal failure. These observations
ave fueled increasing interest in nonloop diuretic ap-
roaches for the management of venous congestion in acute
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targeted at management of worsening renal function or
diuretic resistance in the context of heart failure, including
adenosine-receptor antagonists (11), natriuretic peptides
(12), inotropes (13), and vasopressin antagonists (14), have
provided disappointing results.
An alternative approach to decongestion is the direct
mechanical removal of salt and water through ultrafiltration
(15). Conventional dialysis, particularly peritoneal dialysis,
frequently has been used clinically for this purpose, although
evidence supporting the routine use of this approach is
lacking. The development of technology for bedside
aquapheresis through peripheral venous catheters has fueled
enthusiasm for this approach as an upfront alternative to
diuretic treatment for patients with acute decompensated
heart failure, with data from recent randomized controlled
clinical trials supporting the potential benefits of this ap-
proach on weight loss, exercise capacity, hemodynamics,
and hospitalizations for heart failure (16,17).
In this issue of the Journal, Patarroyo et al. (18) present
data that illuminate the position of slow continuous ultra-
filtration in the management of decompensated and recal-
citrant heart failure. The population studied included a
highly selected group of 63 patients with advanced heart
failure, worsening renal function, and congestion refractory
to intensive attempts at hemodynamically guided medical
therapy using a pulmonary arterial catheter. The selection
criteria identified an extremely ill population of patients
with left ventricular ejection fraction of 26  15%, serum
sodium of 133  6 mEq/l, baseline creatinine of 1.9  0.8
mg/dl, mean central venous pressure of 20 mm Hg, mean
pulmonary capillary wedge pressure of 30 mm Hg, and
cardiac index of 1.8 l/min/m2 defining hemodynamics
consistent with cardiogenic shock (18% were treated with
inotropes at baseline). After 48 h of ultrafiltration, a
reduction in filling pressures and an increase in cardiac index
were noted, but without significant improvement in blood
urea nitrogen or serum creatinine levels. After initiation of
ultrafiltration, 59% of these advanced HF patients required
conversion to continuous dialysis during the hospital course,
and 14% were dependent on dialysis at discharge. Despite
effective decongestion, as perhaps may be expected for this
population with advanced disease refractory to conventional
therapy, in-hospital mortality was high, with 19 (30%) of 63
patients dying before discharge and 6 additional patients
discharged to terminal care in hospice.
Although this is a small patient sample from a single
center, these sobering data clearly highlight the limitations
of ultrafiltration as salvage therapy for patients with wors-
ening renal function in the setting of advanced, medically
refractory heart failure. The study presents a counterpoint to
recent studies highlighting potential short-term benefits to
ultrafiltration in acute decompensated heart failure and
earlier observations regarding the usefulness of dialysis in
patients with refractory heart failure (19–21). As the au-
1914 Weinrauch et al. JACC Vol. 60, No. 19, 2012
Ultrafiltration in Heart Failure November 6, 2012:1913–5thors concede, renal replacement was offered in this popu-
lation as a therapy of desperation in the face of failure of
conventional methods, in the hope that effective deconges-
tion might provide sufficient hemodynamic benefit to re-
verse the downward spiral of cardiorenal deterioration. The
observation that volume removal improved hemodynamic
parameters without a major influence on clinical outcomes
and may have accelerated deterioration in renal function for
a substantial subset of patients is an important cautionary
note about the limitations of medical therapy in the setting
of end-stage disease.
Although limited data regarding baseline renal function
are provided in this report, the aggregate experience sug-
gests that those with creatinine clearance of less than
20 ml/minute would be at particularly high risk for perma-
nent dialysis after rescue ultrafiltration, whereas those with
creatinine clearance of more than 40 ml/minute may be
managed successfully with recovery of native kidney func-
tion. Better risk stratification algorithms incorporating for-
mal assessment of glomerular filtration rate as well as other
clinical and laboratory parameters may add precision to the
decision-making process. Whether patients with a lesser
severity of heart failure might benefit from ultrafiltration as
an upfront or salvage approach to diuretic resistance or
cardiorenal syndrome is the subject of ongoing clinical trials
(22). However, the notion that some patients with heart
failure may be beyond salvage even with heroic efforts
involving mechanical support resonates with observations
from the ventricular assist device literature highlighting
the lack of benefit with urgent implantation of durable
mechanical circulatory support in refractory cardiogenic
shock (INTERMACS [Interagency Registry for Mechani-
cally Assisted Circulatory Support] Profile 1) (23).
As the arsenal of available therapies for management of
end-stage heart failure expands, it becomes increasingly
important to define the margins of medical futility to
prevent unnecessary prolongation of the dying process for
patients and their families and exposure of patients to risk
and discomfort with possible unrealistic expectations that
they will return to an acceptable health status. A recent
statement from the American Heart Association, on deci-
sion making in advanced heart failure highlights the impor-
tance of considering the overall trajectory of illness and
patient preferences in the selection of medical treatments
near the end of life (24). Therapies (e.g., defibrillation,
dialysis resynchronization) that may improve quality or
duration of life during the early phases of disease may be less
effective and desirable as disease nears the end stage. In the
oncology population, earlier introduction of palliative care
considerations has been shown to improve quality of life for
patients and families without shortening survival (25).
Recognition and acknowledgment of disease progression
similarly may facilitate early introduction of palliative ap-
proaches for symptom management in a heart failure
population with a similar symptom burden and prognosis.
Physicians caring for heart failure patients increasingly musttake responsibility for helping patients to make the delib-
erate choice not to engage high-risk therapies that are
unlikely to influence the ultimate outcome and indeed may
impair quality of life during the limited time that remains.
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